The Phase 3 LIVERAGE entry, sponsored by Boehringer Ingelheim, was last updated on 1 October 2026.
Bethesda, Maryland, 1 October 2026 — The ClinicalTrials.gov registry record with identifier NCT06632444, a Phase 3 interventional study sponsored by Boehringer Ingelheim, was last updated on 1 October 2026 and carries the overall status recruiting. The registered brief title names moderate or advanced liver fibrosis as the registered population characteristic.
Source documents
-
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Identifier
- Registry identifier NCT06632444
- Registry status
- RECRUITING
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Last update posted
- 2026-10-01